Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose versus medium-dose ITI with domestic recombinant factor VIII in children with severe hemophilia A and high-titer inhibitors
ChiCTR2200056603Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of recombinant coagulation factor viii in hemophilia A (2 arms), sponsored by Beijing Children's Hospital. Primary endpoint: ITI success rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
recombinant coagulation factor viii
03
Conditions
hemophilia A
Beyond the preview
Go deeper on ChiCTR2200056603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056603.